ArticleAmerican journal of hematology2023

The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.

Elias J Jabbour et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.